Marketing: Page 2

  • Pear Therapeutics prescription digital therapeutic Somryst for chronic insomnia
    Image attribution tooltip
    Permission granted by Pear Therapeutics

    Pear Therapeutics undergoes another round of layoffs, cutting 22% of staff

    The digital therapeutics company said the reductions will extend its cash runway and curb its reliance on financing.

    By Elise Reuter • Nov. 15, 2022
  • GlaxoSmithKline CEO Emma Walmsley
    Image attribution tooltip
    Courtesy of GSK Flickr page

    Under FDA pressure, GSK limits use of ovarian cancer drug

    The drugmaker’s decision is the latest fallout from safety concerns that have emerged in testing of so-called PARP inhibitors, resulting in withdrawals by Merck & Co., AstraZeneca and Clovis Oncology. 

    By Nov. 11, 2022
  • Alexis Borisy and Melanie Nallicheri of EQRx, at launch
    Image attribution tooltip
    Courtesy of EQRx

    EQRx redraws ‘radical’ drug pricing plans for first two drugs

    The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.

    By Nov. 10, 2022
  • Image attribution tooltip
    Novo Nordisk
    Obesity drugs

    Novo obesity drug sales lag as manufacturing problems persist

    Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.

    By Nov. 2, 2022
  • Lilly sales of new diabetes drug accelerate on rising patient demand

    Company executives highlighted the “viral nature” of demand for Mounjaro, which was approved in May for diabetes and has also shown a strong weight-loss benefit in clinical testing.

    By Nov. 1, 2022
  • Two employees walk down a hallway in Gilead's Kite cell therapy unit.
    Image attribution tooltip
    Gilead Sciences Inc. / Kite Pharma

    Gilead, fueled by latest approval, sees CAR-T sales take off

    After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and J&J.

    By Oct. 28, 2022
  • Image attribution tooltip

    Novartis sales of Zolgensma gene therapy slow as market shifts

    Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.

    By Oct. 25, 2022
  • A close up of the Pfizer BioNTech vaccine on December 23, 2021 in Poole, England.
    Image attribution tooltip
    Finbarr Webster via Getty Images

    Pfizer planning steep price hike for COVID-19 vaccine

    The company is considering charging as much as between $110 and $130 per dose — roughly four times the vaccine’s current price — once sales transition to the private market.

    By Oct. 21, 2022
  • A person wearing a lab coat looks on at a laptop at a table. There is notebook beside the laptop, and two people in lab coats out of focus in the background..
    Image attribution tooltip Arcurs

    Sponsored by First Republic Bank

    Building the dream team: How life science startups can attract top talent

    Learn how to attract and retain top talent, in an ultra-competitive labor market.

    By Nishta Rao, Managing Director, Life Science, First Republic Bank • Oct. 17, 2022
  • GoodRx's provider mode platform
    Image attribution tooltip
    Courtesy of GoodRx

    GoodRx launches new push to draw in doctors

    Targeting providers directly is a pivot for GoodRx, but the company sees an opportunity to capture more pharmaceutical advertising revenue, said executive Preeti Parikh.

    By Hailey Mensik • Oct. 13, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    Omicron boosters from Pfizer, Moderna cleared by FDA for younger children

    Pfizer's reformulated vaccine is now authorized for use in children at least 5 years of age, while Moderna's will be available for kids as young as 6.

    By Oct. 12, 2022
  • Obesity drugs

    Lilly looks to speed FDA review of new diabetes drug in obesity

    A new fast track designation allows Lilly to begin the process of seeking approval of tirzepatide for obesity, though the drug will need to succeed in a second trial to get to market.  

    By Oct. 6, 2022
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen

    Biogen to pay $900M to settle lawsuit over MS drug outreach

    A former Biogen employee sued in 2012, alleging the company paid physician fees to encourage prescribing of its drugs. Biogen did not admit wrongdoing as part of the settlement.

    By Sept. 27, 2022
  • Sponsored by flipMD from GoodRx

    Optimizing pharmaceutical innovation

    Elevate pharma product development and marketing through collaboration with physician experts

    Sept. 19, 2022
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi

    Sanofi, AstraZeneca secure EMA support for RSV drug in babies

    If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants. 

    By Sept. 16, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers gets FDA approval for new type of psoriasis drug

    Sotyktu has been on the pharma’s top pipeline candidates and its clearance continues a string of positive regulatory news for the company.

    By Updated Sept. 12, 2022
  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA names new head to vaccine review office

    David Kaslow, the lead scientist at a global public health nonprofit, will succeed Marion Gruber, who retired last fall amid her dissent on the timing of COVID-19 vaccine boosters.

    By Sept. 9, 2022
  • Image attribution tooltip
    Getty Images

    FDA holds back Alvotech’s Humira biosimilar over manufacturing issues

    The company received a complete response letter, but still expects to win approval of the copycat drug in time to launch it in the U.S. next year.

    By Sept. 6, 2022
  • a nurse gives a vaccination to a woman sitting in a chair
    Image attribution tooltip
    Joe Raedle/Getty Images via Getty Images

    Funds for free COVID-19 vaccines could run out as early as January, HHS says

    The commercial market for COVID-19 vaccinations could be similar to that for seasonal flu shots and other vaccines, an official with the department said.

    By Sydney Halleman • Aug. 31, 2022
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell / BioPharma Dive

    Incyte secures second approval for targeted cancer drug

    Sold as Pemazyre, the drug, which blocks well-known cancer proteins known as FGFRs, is now also cleared for use in certain patients with very rare and aggressive blood cancers.

    By Aug. 29, 2022
  • Magic Mushrooms in laboratory. Psilocybin science and research. Person examining fungi.
    Image attribution tooltip
    24K-Production via Getty Images
    Sponsored by Worldwide Clinical Trials

    Psychedelic clinical trials: What sponsors should know when designing new protocols

    With regulators and lawmakers seemingly on board, sponsors have more opportunities than ever to pursue clinical research in this high-velocity area.

    Aug. 29, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images

    Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology

    The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.

    By Aug. 26, 2022
  • Image attribution tooltip
    Jacob Bell

    Novartis begins plans to spin off generic drug business

    After reviewing multiple options including a possible sale, the Swiss drugmaker said spinning off Sandoz would give the division “greater freedom to operate” and capitalize on newly growing sales.

    By Aug. 25, 2022
  • A sign at Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences

    Gilead breaks through with first approval for new HIV drug

    European authorities cleared Gilead’s long-acting shot for patients whose HIV infection is resistant to other drugs. An FDA decision is expected by December.

    By Aug. 22, 2022
  • A child plays EndeavorRx on a tablet. The digital therapeutic intended to improve attention in kids with ADHD.
    Image attribution tooltip
    Permission granted by Akili Interactive

    Digital medicine company Akili gets cold market reception after blank-check merger

    After spiking on news of the merger’s close, shares in the ADHD treatment developer fell sharply in trading.

    By Elise Reuter • Updated Aug. 23, 2022